Anupam Rasayan guides FY27 revenue at ₹4,800–5,000 Cr

ANURAS Anupam Rasayan India Limited (ANURAS) has guided for FY27 consolidated revenue of ₹4,800–5,000 Cr. EBITDA margin guidance is at 23%, with H2 FY27 expected to be very strong Management indicated that consolidation of recent acquisitions has been completed. H2 FY27 is expected to deliver ₹2,400–2,500 Cr in revenue, supported by full contribution from acquired businesses and new contracts. The company anticipates organic growth of 20–25% over the medium term, with acquisition synergies and improved product mix supporting margins. The key triggers are the FY27 revenue guidance of ₹4,800–5,000 Cr and the expectation of a strong H2, backed by completed acquisition consolidation. This supports the company’s specialty chemicals and pharma expansion strategy. Peers such as Aarti Industries, Navin Fluorine and Vinati Organics may face comparison on growth outlook and margin trajectory. Near-term prices could react positively to the strong revenue guidance and H2 visibility. Risks include slower-than-expected contribution from acquisitions, demand softness in end markets, or margin pressure from input costs. Competitors listed: Aarti Industries, Navin Fluorine, Vinati Organics. We have no financial interest in this news.